OSI at buy by Merrill

Merrill Lynch analyst Eric Ende reiterated OSI Pharmaceuticals, Inc. at a buy. The outlook for the company's Tarceva in pancreatic cancer is improved after Genentech stopped its phase 3 trial of Avastin. Tarceva may become more of an anchor for therapy in pancreatic cancer in combination, with Roche testing Tarceva plus Avastin in front-line pancreatic cancer. Shares of the Melville, N.Y.-based pharmaceutical company were up 96 cents, or 3.01%, at $32.84 on volume of 2,166,354 shares versus the three-month running average of 1,149,880 shares. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.